Stay updated on Pembrolizumab in Advanced NSCLC: 2nd Line Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab in Advanced NSCLC: 2nd Line Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab in Advanced NSCLC: 2nd Line Clinical Trial page

  1. Check
    7 days ago
    Change Detected
    Summary
    The related topics section loses three items: Lung cancer, related topics:, and MedlinePlus Genetics, narrowing the list of disease tags and external resources associated with the study.
    Difference
    0.1%
    Check dated 2026-05-23T14:14:23.000Z thumbnail image
  2. Check
    14 days ago
    Change Detected
    Summary
    The page revision label was updated from v3.5.3 to v3.5.4, indicating a minor update to the study record. This does not appear to alter the study details themselves.
    Difference
    0.0%
    Check dated 2026-05-16T10:16:09.000Z thumbnail image
  3. Check
    21 days ago
    No Change Detected
  4. Check
    29 days ago
    No Change Detected
  5. Check
    36 days ago
    Change Detected
    Summary
    The page footer revision tag was updated from **v3.5.2** to **v3.5.3**, indicating a site/platform version update rather than a change to the study information.
    Difference
    0.0%
    Check dated 2026-04-24T22:24:17.000Z thumbnail image
  6. Check
    43 days ago
    Change Detected
    Summary
    Added related topics: Lung cancer and MedlinePlus Genetics. Updated the page revision from v3.5.0 to v3.5.2.
    Difference
    0.2%
    Check dated 2026-04-17T14:13:13.000Z thumbnail image
  7. Check
    50 days ago
    Change Detected
    Summary
    Removed the Lung cancer topic and the MedlinePlus Genetics related topic from the study's topics section. This may reduce discoverability for NSCLC-related searches and related genetic resources.
    Difference
    0.1%
    Check dated 2026-04-10T09:00:25.000Z thumbnail image
  8. Check
    58 days ago
    Change Detected
    Summary
    Added related topics to the study page: Lung cancer and MedlinePlus Genetics.
    Difference
    0.1%
    Check dated 2026-04-03T05:39:05.000Z thumbnail image

Stay in the know with updates to Pembrolizumab in Advanced NSCLC: 2nd Line Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Advanced NSCLC: 2nd Line Clinical Trial page.